Momentum Stocks: Spirit Realty Capital, Inc. (NYSE:SRC), Vascular Biogenics (NASDAQ:VBLT), HudBay Minerals (NYSE:HBM), Charles River Laboratories International (NYSE:CRL), Enterprise Products Partners (NYSE:EPD)

Spirit Realty Capital, Inc. (NYSE:SRC) belongs to Financial sector. Its net profit margin is -3.70% and weekly performance is 2.63%. On last trading day company shares ended up $10.14. Spirit Realty Capital, Inc. (NYSE:SRC) distance from 50-day simple moving average (SMA50) is -3.75%. Spirit Realty Capital, Inc. (NYSE:SRC) announced that its Board of Directors has declared a quarterly cash dividend of $0.1700 per common share, which represents an annualized rate of $0.6800 per common share. Shareholders of record as of June 30, 2015, will receive the $0.1700 cash dividend on July 15, 2015.

Vascular Biogenics Ltd. (NASDAQ:VBLT) shares increased 5.45% in last trading session and ended the day at $6.19. VBLT return on assets is -33.90%. Vascular Biogenics Ltd. (NASDAQ:VBLT) quarterly performance is 34.57%.

On 10 July, HudBay Minerals, Inc. (NYSE:HBM) shares moved down -1.83% and was closed at $7.53. HBM EPS growth in last 5 year was -42.78%. HudBay Minerals, Inc. (NYSE:HBM) year to date (YTD) performance is -13.25%. HudBay Minerals (NYSE:HBM) had its target price lowered by Canaccord Genuity from C$13.00 to C$12.00 in a research note released on Friday morning, Analyst Ratings.Net reports. They currently have a hold rating on the mining company’s stock.

Charles River Laboratories International, Inc. (NYSE:CRL) ended the last trading day at $73.29. Company weekly volatility is calculated as 2.40% and price to cash ratio as 20.81. Charles River Laboratories International, Inc. (NYSE:CRL) showed a weekly performance of 5.39%. Charles River Laboratories International, Inc. (NYSE:CRL) announced that it has entered into a definitive agreement to acquire Celsis International Ltd. for $212 million in cash, subject to customary closing adjustments. Celsis is a leading provider of rapid bacterial detection systems for quality control testing in the biopharmaceutical and consumer products industries. Celsis’s systems are principally used for product-release testing to help ensure the safe manufacture of drugs and consumer products.

Enterprise Products Partners L.P. (NYSE:EPD) shares advanced 1.70% in last trading session and ended the day at $30.53. EPD Gross Margin is 8.40% and its return on assets is 5.90%. Enterprise Products Partners L.P. (NYSE:EPD) quarterly performance is -9.57%.Enterprise Products Partners (NYSE: EPD) declared a quarterly dividend of $0.38 per share, or $1.52 annualized. This is a 1.3% increase from the prior dividend of $0.375. The dividend will be payable on August 7, 2015, to stockholders of record on July 31, 2015, with an ex-dividend date of July 29, 2015.

Leave a Reply

Your email address will not be published. Required fields are marked *